Agree Realty: GlycoNex Partners with Hokkaido University to Advance Gastric Cancer Treatment
- GlycoNex partners with Hokkaido University Hospital to advance gastric cancer treatment with GNX1021 antibody-drug conjugate.
- The collaboration aims to identify patient populations benefiting from GNX1021 by analyzing bLeB/Y glycan expression.
- GlycoNex plans to initiate Phase I clinical trials for GNX1021 by 2026 after completing pre-fill and toxicology testing.
Innovative Collaboration Aims to Enhance Gastric Cancer Treatment Options
GlycoNex, Inc., a clinical-stage biotechnology company based in New Taipei City, announces a significant partnership with Hokkaido University Hospital to advance its promising glycan-directed antibody-drug conjugate (ADC), GNX1021, specifically targeting gastric cancer. Gastric cancer is identified as the third most prevalent cancer and the fourth leading cause of cancer-related deaths in Japan, with projections indicating 115,100 new cases and 39,900 deaths in 2024. The collaboration intends to conduct a retrospective study that will analyze the expression of the branched Lewis B/Y (bLeB/Y) glycan antigen in gastric cancer patients, a critical step in identifying patient populations that may benefit from GNX1021 treatment.
This partnership aims to assess the correlation between bLeB/Y expression and established clinical biomarkers, including HER2, CLDN18, PD-L1, and MMR. Dr. Mei-Chun Yang, CEO of GlycoNex, highlights the collaboration's potential to develop novel treatment strategies for gastric cancer, addressing significant unmet needs in oncology beyond existing HER2- and CLDN18-targeted therapies. The inquiry into bLeB/Y expression marks a promising avenue for refining patient selection criteria, ensuring that those most likely to respond to GNX1021 are identified and treated effectively.
With pre-fill and toxicology testing already completed, GlycoNex is poised to seek regulatory approvals in Taiwan and Japan, with plans to initiate Phase I clinical trials for GNX1021 by 2026. This initiative not only underscores GlycoNex's commitment to enhancing treatment options for gastric cancer patients but also positions the company as a vital contributor to the advancement of next-generation biologic therapies. The focus on glycan-directed ADCs and high-quality biosimilars further establishes GlycoNex as a pioneer in the oncology landscape, aiming to improve outcomes for patients facing limited treatment alternatives.
In other industry developments, Mabwell, a biopharmaceutical company, has begun its Phase I/II clinical trial for the novel CDH17-targeting ADC, 7MW4911, aimed at treating advanced solid tumors. The trial has already dosed its first patient, representing a significant milestone in the development of effective therapies for advanced colorectal cancer and other gastrointestinal tumors.
Related Cashu News

Lamar Advertising Co Moves to Value Indices Amid Shift in Investment Strategies
Lamar Advertising Co (Ticker: LAMR) has recently undergone a significant change in its market classification by being added to several Russell value and defensive indices. This inclusion reflects a sh…

Alexandria Real Estate Equities Advances Corporate Responsibility and Strengthens Its Position in Life Sciences
Alexandria Real Estate Equities (ARE) has made significant strides in enhancing its corporate responsibility efforts, as detailed in its recently published 2025 Corporate Responsibility Report. The re…

Healthpeak OP LLC Achieves Key Index Inclusion, Boosting Investor Interest and Trading Activity
Healthpeak OP LLC (Ticker: DOC) leverages significant market developments to reinforce its position in the real estate investment trust sector through strategic index inclusion, which may reshape inve…

Public Storage Boosts Financial Flexibility with New Credit Facility and Commercial Paper Program
Public Storage (Ticker: PSA) enhances its financial flexibility with a new unsecured credit facility and commercial paper program. Strategic Financial Innovations The company announces the closure of…

